Honliv Healthcare Management Group Co. Ltd. has announced its interim results for the six months ended 30 June 2025. The Group reported a revenue of RMB346.8 million, a decrease of 16.5% compared to RMB415.2 million in the same period of 2024. Gross profit also saw a decline, falling by 36.1% to RMB45.8 million from RMB71.6 million in the previous year. The Group recorded a loss attributable to owners of the company amounting to RMB673,000, contrasting with a profit of RMB20.0 million in the first half of 2024. This represents a significant change in financial performance. Pharmaceutical sales revenue for the reporting period was RMB138.7 million, reflecting a year-on-year decrease of 15.8% from RMB164.7 million. No specific outlook or guidance was included in the announcement. In terms of research and development, the Group has been active, with hospitals under its management applying for 30 new technologies and projects, of which 13 new technologies have passed the Ethics Committee review. Additionally, medical staff published 30 papers, including one SCI article, indicating ongoing commitment to medical research and development.